SCHEMBL2825013

SCHEMBL2825013

CC(C)(C)COc1c(/C=C/c2nc3sccn3c2C(=O)Nc2ncc(C(F)(F)F)cc2Cl)cccc1OC(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.36
KDM4E B2RXH2 5/20 0.36
HPGD P15428 4/20 0.36
KMT2A Q03164 8/20 0.36
MEN1 O00255 7/20 0.36
POLB P06746 4/20 0.36
L3MBTL1 Q9Y468 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
MAPT P10636 2/20 0.35
HSP90AA1 P07900 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
KLF5 Q13887 1/20 0.35
GAA P10253 4/20 0.35
TDP1 Q9NUW8 2/20 0.35
APEX1 P27695 1/20 0.35
APOBEC3A P31941 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2825016 1.00 ALDH1A1 (0.36) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL13287431 0.90 MEN1 (0.35) ALDH1A1KDM4EHPGDKMT2AMEN1
SCHEMBL2824074 0.88 EPAS1 (0.42) KDM4EKMT2AMEN1POLBSMN1; SMN2
SCHEMBL2824070 0.88 EPAS1 (0.42) KDM4EKMT2AMEN1POLBSMN1; SMN2
SCHEMBL2367968 0.84 HRH4 (0.36) KMT2AMEN1RAB9AGAATDP1
SCHEMBL2827672 0.83 NPC1 (0.32) ALDH1A1HPGDKMT2AMEN1RAB9A
SCHEMBL2827674 0.83 NPC1 (0.32) ALDH1A1HPGDKMT2AMEN1RAB9A
SCHEMBL2829848 0.83 HTT (0.34) KDM4EHPGDPOLBSMN1; SMN2MAPT
SCHEMBL2829845 0.83 HTT (0.34) KDM4EHPGDPOLBSMN1; SMN2MAPT
SCHEMBL2368441 0.83 HTT (0.31) HPGDSMN1; SMN2HTTRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318928-B2 Fused imidazole carboxamides as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-11-27 US claimed
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A (CH) 2010-06-17 US claimed
US-8318928-B2 Fused imidazole carboxamides as TRPV3 modulators GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-11-27 US disclosed
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A (CH) 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152192-A1 FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS TRPV3, TRPV1, TRPV2 ALDH1A1 2705/4885KDM4E 3190/4885HPGD 798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.